Aseptic necrosis of the knee: bone scintigraphy.

R. Burt,T. J. Matthews

DOI: https://doi.org/10.2214/AJR.138.3.571

1982-03-01

Abstract:

What problem does this paper attempt to address?

Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients

Yael Renert-Yuval,Khaled Ezzedine,Pearl Grimes,David Rosmarin,Lawrence F. Eichenfield,Leslie Castelo-Soccio,Victor Huang,Seemal R. Desai,Samantha Walsh,Jonathan I. Silverberg,Amy S. Paller,Michele Rodrigues,Mark Weingarten,Shanthi Narla,Jackie Gardner,Michael Siegel,Sidra Ibad,Nanette B. Silverberg

DOI: https://doi.org/10.1001/jamadermatol.2024.0021

IF: 11.816

2024-03-13

JAMA Dermatology

Abstract:Importance Evidence-based recommendations for the treatment of vitiligo in pediatric, adolescent, and young adult patients in the US are needed. Objective To develop evidence- and consensus-based expert recommendations on the diagnosis and treatment of vitiligo in young patients. Evidence Review A process was developed to produce consensus recommendations addressing questions regarding pediatric vitiligo. A librarian-conducted literature review was performed using articles that met the inclusion criteria: published in English, containing primary data (including meta-analysis) and pediatric-specific data, and analysis of 6 or more patients. Included articles were graded by the Strength of Recommendation Taxonomy criteria and Oxford Centre for Evidence-based Medicine’s Levels of Evidence and Grades of Recommendation. Research questions were reviewed on May 9, 2022, through a video conference. One month after the conference, participants participated in an online survey documenting their level of agreement with the generated statements, using a 5-point Likert scale. Findings Articles on topical corticosteroids and/or topical calcineurin inhibitors (n = 50), topical Janus kinase inhibitors (n = 5), pseudocatalase (n = 2), and microdermabrasion (n = 2) met inclusion criteria. Forty-two recommendations were made on the diagnosis of vitiligo and optimal topical therapeutics, with 33 recommendations obtaining a 70% or greater composite agreement and strong agreement. Topical calcineurin inhibitors twice daily, topical corticosteroids with time limitation due to atrophy risk, and topical ruxolitinib, 1.5%, cream—used off-label for patients younger than 12 years and limited to nonsegmental vitiligo—were identified as evidence-based first-line therapies in the management of pediatric and adolescent patients, with specific guidance on age-based data, minimum therapeutic trial of 6 months or greater, prolonged therapy to prevent recurrence, and the positive benefit of coordinated use of UV therapeutic sources. Conclusions and Relevance Evidence supports the use of topical calcineurin inhibitors, topical corticosteroids, and topical Janus kinase inhibitors as effective therapeutics for vitiligo in pediatric, adolescent, and young adult patients, with specific decisions on choice of agent based on factors such as site location, body surface area, and age.

dermatology
Guideline for the diagnosis and management of vitiligo

D.J. Gawkrodger,A.D. Ormerod,L. Shaw,I. Mauri‐Sole,M.E. Whitton,M.J. Watts,A.V. Anstey,J. Ingham,K. Young,I. Mauri-Sole

DOI: https://doi.org/10.1111/j.1365-2133.2008.08881.x

IF: 11.113

2008-10-20

British Journal of Dermatology

Abstract:This detailed and user-friendly guideline for the diagnosis and management of vitiligo in children and adults aims to give high quality clinical advice, based on the best available evidence and expert consensus, taking into account patient choice and clinical expertise. The guideline was devised by a structured process and is intended for use by dermatologists and as a resource for interested parties including patients. Recommendations and levels of evidence have been graded according to the method developed by the Scottish Inter-Collegiate Guidelines Network. Where evidence was lacking, research recommendations were made. The types of vitiligo, process of diagnosis in primary and secondary care, and investigation of vitiligo were assessed. Treatments considered include offering no treatment other than camouflage cosmetics and sunscreens, the use of topical potent or highly potent corticosteroids, of vitamin D analogues, and of topical calcineurin inhibitors, and depigmentation with p-(benzyloxy)phenol. The use of systemic treatment, e.g. corticosteroids, ciclosporin and other immunosuppressive agents was analyzed. Phototherapy was considered, including narrowband ultraviolet B (UVB), psoralen with ultraviolet A (UVA), and khellin with UVA or UVB, along with combinations of topical preparations and various forms of UV. Surgical treatments that were assessed include full-thickness and split skin grafting, mini (punch) grafts, autologous epidermal cell suspensions, and autologous skin equivalents. The effectiveness of cognitive therapy and psychological treatments was considered. Therapeutic algorithms using grades of recommendation and levels of evidence have been produced for children and for adults with vitiligo.

dermatology
Update on childhood vitiligo

Nanette B Silverberg

DOI: https://doi.org/10.1097/MOP.0b013e32833b6ac3

Abstract:Purpose of review: This review addresses recent changes in the understanding and the treatment of vitiligo vulgaris. Recent findings: Two target genes for vitiligo have been identified, NACHT-leucine-rich-repeat protein-1 (NALP1), part of the inflammasome cascade, and tyrosinase, the enzyme that produces melanin. Identification of reactive oxidation species has furthered the understanding of melanocyte destruction. Comorbid autoimmune disease, including thyroid autoimmunity seen in 25%, is genetically linked to generalized vitiligo and is noted in both childhood vitiligo patients and their families. Screening for vitamin deficiencies and concurrent autoimmunity can be beneficial to the overall health of the child with vitiligo. About half of all vitiligo vulgaris patients have onset of their illness during childhood, causing increased psychological stress during the formative years. Fortunately, therapy has improved as well, with the development of newer topical agents for vitiligo, including topical calcineurin inhibitors; new topical combinations such as topical corticosteroids and calcipotriene; and new technological advances including narrowband ultraviolet B and excimer laser. Summary: A cyclic approach to therapy should be used wherein topical agents are altered every 6-8 months and technology is used as an alternative after achievement of maximal topical response. With cyclic therapy and early disease intervention, good cosmetic outcomes may be achievable, particularly in localized cases.
Childhood facial vitiligo: how intractable is it?

S. A. Kim,S. Cho,S. H. Kwon,J. T. Park,J. I. Na,C. H. Huh,K. C. Park

DOI: https://doi.org/10.1111/jdv.12666

2014-08-29

Journal of the European Academy of Dermatology and Venereology

Abstract:BACKGROUND: Following the recent elucidation of its pathogenic mechanisms involving reactive oxygen species, use of vitamins, folic acid and antioxidants as adjuvant therapy has been suggested.OBJECTIVE: To evaluate the long-term outcome of childhood facial vitiligo who were treated with nutritional education, vitamin E (α-tocopherol 100-400 IU/day), folic acid (1-2 mg/day) and multivitamin intake and antioxidant cosmetics as the mainstay of treatment as well as the conventional therapies including oral, topical and/or intralesional corticosteroid, topical macrolactam, Excimer laser and epidermal graft.METHODS: Medical data and photographs of 111 paediatric facial vitiligo patients who had been followed up for longer than 1 year from March 1, 2003 to June 30, 2013 were extracted from data warehouse of electric medical records. Photographic evaluation and final visual outcome assessment was performed.RESULT: By investigator's assessment, 9% of patients demonstrated no improvement regardless of treatment modality, whereas 91% showed improvement of lesions. Among the latter, 33.3% resulted in >75% improvement; 18% in 50%-75% improvement; 26.1% in 25%-50% improvement; and 13.5% in <25% improvement. In the final visual outcome assessment, 'Looking excellent' was seen in 42.3%; 'looking very good' in 30.6%; 'looking good' in 17.1%; 'looking fair' in 9.0%; and 'looking bad' in 0.9%.CONCLUSION: Although childhood facial vitiligo is quite refractory to treatment, the long-term outcome of this condition is not dismal with conventional vitiligo therapy along with basic nutritional therapeutic regimen.

dermatology
Practices in Pediatric Cosmetic Dermatologic Procedures: A National Survey

Lauren Hoffman,Sarah Ahmed,Andrew C. Krakowski,Anne Chapas

DOI: https://doi.org/10.1097/dss.0000000000004287

2024-06-18

Dermatologic Surgery

Abstract:BACKGROUND Adult populations have traditionally been the primary recipients of cosmetic treatments, but a growing trend shows an increase in such procedures among pediatric patients. OBJECTIVE The objective of the authors' study was to investigate types of procedures currently being performed by pediatric and cosmetic dermatologists and factors that may influence their choice of treatments in a pediatric population. METHODS The authors conducted an anonymous online survey targeting healthcare practitioners who frequently use lasers for pediatric cutaneous conditions. The survey collected information on participants' primary scope of practice, pediatric cosmetic procedures they performed, counseling topics, and procedural details. RESULTS Of 85 survey respondents, 73 (86.00%) completed all questions. Most respondents identified as pediatric dermatologists (77.65%), followed by general dermatologists (18.82%), cosmetic dermatologists (8.24%), and dermatologic/Mohs surgeons (1.18%). Top pediatric cosmetic conditions treated included hypertrophic/traumatic scars (95.29%), acne (89.41%), axillary and facial hyperhidrosis (77.65%), hypertrichosis/hirsutism (67.06%), and pigmented lesion removal (64.71%). Commonly performed procedures were vascular lasers (77.65%), laser hair removal (50.59%), and pigmented lasers (28.24%), among others. Respondents prioritized understanding risks/benefits, clinically indicated treatment, and the natural course of the condition. CONCLUSION As the first multisociety, national survey, these results offer valuable insight into the current landscape of pediatric cosmetic treatments from the perspective of dermatologists.

dermatology,surgery
Pediatric Dermatology for People of Color

Muayad M. Shahin,Henry T. Quach,Kalyani S. Marathe

DOI: https://doi.org/10.3928/19382359-20240205-07

2024-04-01

Pediatric Annals

Abstract:When evaluating pediatric patients of color, it is essential to consider the unique diagnostic and treatment factors that apply to this population. Certain dermatologic conditions are more common in these patients, including postinflammatory hyperpigmentation, pityriasis alba, progressive macular hypomelanosis, tinea capitis, traction alopecia, keloids, hypertrophic scars, pseudofolliculitis barbae, acne keloidalis nuchae, and hidradenitis suppurativa. Furthermore, conditions such as vitiligo are more noticeable in people of color. This can lead to a significantly diminished quality of life, so these conditions should be quickly recognized and treated. Notably, inflammation can be difficult to recognize on the skin of people of color, which can lead to the underestimation of severity as well as inappropriate treatment. Treatment recommendations can also differ based on lifestyle or cultural norms, such as the use of tinted sunscreens and the consideration of hair care practices. Pediatricians should be aware of these conditions and treatment considerations to best treat pediatric patients of color. [ Pediatr Ann . 2024;53(4):e146–e151.]

pediatrics
Therapeutic interventions to lessen the psychosocial effect of vitiligo in children: A review

Simi D. Cadmus,Ashley D. Lundgren,Ammar M. Ahmed

DOI: https://doi.org/10.1111/pde.13517

IF: 1.997

2018-05-16

Pediatric Dermatology

Abstract:Vitiligo commonly affects children, with half of affected individuals experiencing disease onset before the age of 20. Because childhood is a time of advancement in social and psychological development, understanding the extent of the effect of the disease and means of alleviation is crucial. Vitiligo has been shown to decrease children's quality of life, with greater distress in children with highly visible lesions and darker skin tones. This article reviews the literature regarding interventions that have been analyzed in children. Studies evaluating the effect of camouflage, cognitive behavioral therapy, psychological self-help tools, and support groups on the psychosocial aspects of vitiligo were included. The review highlights the ongoing need for studies to better understand the modalities described in this article, as well as others, such as skin dyes, bleaching creams, medical tattooing; week-long camps that cater to children with chronic skin disease; and biofeedback, that might have a role in preventing the psychosocial sequelae of childhood vitiligo.

dermatology,pediatrics
Antigen‐antibody combination assays for blood donor screening: weighing the advantages and costs

S. Laperche

DOI: https://doi.org/10.1111/j.1537-2995.2008.01676.x

2008-04-01

Transfusion

Abstract:
Vitiligo outpatient management in the United States: findings from the 2012–2019 National Ambulatory Medical care Survey (NAMCS)

Gaurav N. Pathak,Anurag N. Pathak,Vibha Mital,Jimmy Dhillon,Steven R. Feldman,Babar K. Rao,Gaurav N. PathakAnurag N. PathakVibha MitalJimmy DhillonSteven R. FeldmanBabar K. Raoa Department of Dermatology,Rutgers Robert Wood Johnson Medical School,Piscataway,New Jerseyb Center for Dermatology Research,Department of Dermatology,Wake Forest University School of Medicine,Winston-Salem,North Carolinac Department of Computer Science,Rutgers University School of Arts and Sciences,New Brunswick,New Jerseyd Department of Pathology,Wake Forest University School of Medicine,Winston-Salem,North Carolinae Department of Social Sciences and Health Policy,Wake Forest University School of Medicine,Winston-Salem,North Carolinaf Department of Dermatology,University of Southern Denmark,Odense,Denmarkg Department of Dermatology,Rao Dermatology,Atlantic Highlands,New Jersey

DOI: https://doi.org/10.1080/09546634.2024.2311793

2024-02-13

Journal of Dermatological Treatment

Abstract:Keywords: To the editor, Vitiligo is an autoimmune disorder associated with high psychosocial burden due to the disease's cosmetic disfigurement. Vitiligo affects about 0.16% of people in the United States (US) including nearly 1.52% of children, and disproportionately affects patients with skin of color ( Citation 1 , Citation 2 ). Treatment options are aimed at restoring skin pigmentation and include topical calcineurin inhibitors and corticosteroids and systemic therapies such as oral corticosteroids, minocycline, and cyclosporine ( Citation 3 , Citation 4 ). Despite the availability of treatment options, approximately 50% of patients do not receive any treatment for vitiligo ( Citation 5 ). This study aims to characterize outpatient management of vitiligo in the US utilizing data from the National Ambulatory Medical Care Survey (NAMCS).

dermatology
Prevalence of psychiatric comorbidities and treatment initiation in African American pediatric patients with vitiligo: A retrospective, single-center, case-control study

Emily Strouphauer,Sana Suhail,Carly Mulinda,Promise Ufomadu,Nicole Nyamongo,Grace Lee,Soo Jung Kim

DOI: https://doi.org/10.1016/j.jdin.2024.07.012

2024-08-16

Abstract:Background: Vitiligo may impact psychosocial development, especially among African American pediatric patients, given heightened visibility and increasing rates of anxiety and depression in this subpopulation. Objective: Evaluate psychiatric comorbidities and treatment initiation in African American pediatric patients. Methods: A total of 327 African American pediatric patients with vitiligo were each matched to 3 patients without vitiligo by age, race, and sex in this case-control study. Prevalence of psychiatric conditions and subsequent initiation of pharmacotherapy and/or psychotherapy were analyzed. Results: Compared to controls, pediatric African American patients with vitiligo were significantly more likely to be diagnosed with depression (P < .001) disruptive behavior disorders (P < .001), eating disorders (P = .013), generalized anxiety disorder (P < .001), substance abuse (P = .011), and suicidal ideation (P = .005). Patients with depression, disruptive behavior disorders, and eating disorders had higher initiation rates (76.5%, 82.1%, and 100%, respectively) for psychiatric treatment compared to those with generalized anxiety disorder and substance abuse (55.3% and 61.5%). Nearly 15% of patients did not initiate treatment for suicidal ideation. Limitations: This retrospective study has a limited sample size in a single institution and does not explore psychiatric treatment efficacy. Conclusions: Better understanding of associated psychological comorbidities and impacts on African American children of vitiligo may improve quality of life and dermatologic outcomes for these individuals.
Real-World Experience of Vitiligo Patients: A Retrospective Chart Review

Chelsea Obeng-Asumeng,Fabian Rodriguez-Bolanos,Melinda Gooderham

DOI: https://doi.org/10.1177/12034754231223699

2024-02-10

Journal of Cutaneous Medicine and Surgery

Abstract:Journal of Cutaneous Medicine and Surgery, Ahead of Print. Background:Vitiligo is a common depigmenting skin disorder with an estimated prevalence of 0.5% to 2% worldwide.Objective:We conducted a study to characterize the presentation of vitiligo in community dermatology clinic setting in Ontario, Canada.Methods:A retrospective cross-sectional study was performed through an electronic chart review at a community dermatology clinic with 2 sites in Ontario, Canada.Results:We found a male to female ratio of 1:1.3. The average age at the time of assessment was 40.8 years (ranging from 7 to 75 years). Sixteen percent of the patients were children (less than 18 years of age). Hands were the most common location for vitiligo (55.8%).Conclusions:Our findings are in keeping with previously described epidemiologic data. To our knowledge, this is the first Canadian study looking at the population in a community setting.

dermatology
Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force—Part 2: Specific treatment recommendations

Julien Seneschal,Reinhart Speeckaert,Alain Taïeb,Albert Wolkerstorfer,Thierry Passeron,Amit G. Pandya,Henry W. Lim,Khaled Ezzedine,Youwen Zhou,Flora Xiang,Steven Thng,Atsushi Tanemura,Tamio Suzuki,David Rosmarin,Michelle Rodrigues,Noufal Raboobee,Georg Pliszewski,Davinder Parsad,Naoki Oiso,Paul Monteiro,Jean Marie Meurant,Nicolle Maquignon,Harvey Lui,Caroline Le Poole,Giovanni Leone,Ai‐Young Lee,Eric Lan,Ichiro Katayama,Richard Huggins,Sang Ho Oh,John E. Harris,Iltefat H. Hamzavi,Somesh Gupta,Pearl Grimes,Boon Kee Goh,Deepti Ghia,Samia Esmat,Viktoria Eleftheriadou,Markus Böhm,Laila Benzekri,Marcel Bekkenk,Jung Min Bae,Augustin Alomar,Marwa Abdallah,Mauro Picardo,Nanja Geel,Caroline Le Poole

DOI: https://doi.org/10.1111/jdv.19450

2023-09-17

Journal of the European Academy of Dermatology and Venereology

Abstract:Background The treatment of vitiligo can be challenging. Up‐to‐date agreed consensus recommendations on the use of topical and systemic therapies to facilitate the clinical management of vitiligo are currently lacking. Objectives To develop internationally agreed‐upon expert‐based recommendations for the treatment of vitiligo. Methods In this consensus statement, a consortium of 42 international vitiligo experts and four patient representatives participated in different online and live meetings to develop a consensus management strategy for vitiligo. At least two vitiligo experts summarized the evidence for different topics included in the algorithms. A survey was then given to a core group of eight experts to resolve the remaining issues. Subsequently, the recommendations were finalized and validated based on further input from the entire group during two live meetings. Results The recommendations provided summarize the latest evidence regarding the use of topical therapies (steroids, calcineurin inhibitors and Jak‐inhibitors) and systemic therapies, including steroids and other systemic immunomodulating or antioxidant agents. The different modalities of phototherapies (NB‐UVB, photochemotherapy, excimer devices and home phototherapy), which are often combined with other therapies, are also summarized. Interventional approaches as well as depigmentation strategies are presented for specific indications. Finally, the status of innovative and targeted therapies under development is discussed. Conclusions This international consensus statement culminated in expert‐based clinical practice recommendations for the treatment of vitiligo. The development of new therapies is ongoing in vitiligo, and this will likely improve the future management of vitiligo, a disease that still has many unmet needs.

dermatology
Dermatology for the pediatrician: Advances in diagnosis and treatment of common and not-so-common skin conditions

Joan Tamburro

DOI: https://doi.org/10.3949/ccjm.82.s1.04

Abstract:Advances have been made in understanding and treating both common and rare dermatologic conditions. Atopic dermatitis benefits from bathing and ceramide moisturizers. Common allergic contact dermatitis may have specific presentations. Tinea capitis is effectively treated with terbinafine. Infantile hemangiomas should be treated early in the disease course and respond well to propranolol; any white sign of ulceration should be noted. Localized alopecia areata responds well to topical clobetasol, avoiding the need for intralesional injections. Topical rapamycin can be used to treat tuberous sclerosis. Further understanding of genetics will help guide pediatricians to the proper diagnosis and treatment of skin conditions.
Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy

Torello Lotti,Jana Hercogova,Giuseppe Fabrizi

DOI: https://doi.org/10.1517/14656566.2015.1087508

2015-09-15

Expert Opinion on Pharmacotherapy

Abstract:INTRODUCTION: Vitiligo is a skin disorder characterized by a progressive depigmentation, which is caused by the loss of melanocytes at the cutaneous level. A shift of the immune system with a prevalence of T helper (Th)1/Th17 response instead of a Tregs/Th2 one and may be part of etiology of 10 vitiligo.AREAS COVERED: This review describes the major points of vitiligo onset and shows the cutting-edge results in the field of low-dose medicine in the treatment of dermatologic diseases and, in particular. in vitiligo. In this review on advances in vitiligo pharmacotherapy, the most pertinent recent publications are reported. Electronic databases such as PubMed were searched for terms 'low-dose medicine' or 'low dose and vitiligo' or 'low dose and psoriasis.'EXPERT OPINION: The availability of a systemic treatment for vitiligo, based on the oral administration of low-dose activated signaling molecules represents an opportunity for the dermatologists to overcome some specific pitfalls of currently available therapeutic protocols.

pharmacology & pharmacy
Perception of skin cancer risk and sun protective practices in individuals with vitiligo: a prospective international cross-sectional survey

Sarah Gonzalez,Arielle Carolina Mora Hurtado,Nicole C. Syder,Jack Rodman,Nada Elbuluk

DOI: https://doi.org/10.1007/s00403-024-02942-0

2024-05-24

Archives of Dermatological Research

Abstract:Many individuals with vitiligo are uncertain about their skin cancer risk, phototherapy risks, and recommended sun protective practices. This study examined the perceived skin cancer risk and sun protective practices among individuals living with vitiligo. A secondary objective was to understand where participants obtain this information. This was a prospective cross-sectional study. An online survey was distributed to vitiligo support group leaders globally who shared the survey with their members. Individuals over the age of 18 and with vitiligo were included. There were 209 survey respondents, the majority were between the ages 35–54 (45.5%, n = 95), female (70.8%, n = 148), White (66.0%, n = 138). Nearly half of respondents believed they were at increased risk of skin cancer because of their vitiligo (45.5%, n = 95) and nearly a quarter (22.5%, n = 47) believed that phototherapy increased their risk of skin cancer. Having vitiligo affected sun protective practices with less than a quarter (24.4%, n = 51) of respondents using sunscreen daily or often prior to their vitiligo diagnosis in comparison to the majority of respondents (60.3%, n = 126) using it after their vitiligo diagnosis. The three most common sources where patients obtained information were the internet and social media (46.4%, n = 97), vitiligo support groups (23.4%, n = 49), and dermatologists (20.6%, n = 43). Despite evidence indicating a decreased risk of skin cancer in individuals with vitiligo and supporting the safety of narrowband ultraviolet B phototherapy, many participants believed they were at an increased risk of skin cancer. Findings were sub-stratified and showed differences in sunscreen usage based on gender, skin color, and percent depigmentation. This study also found nearly half of respondents obtained information related to vitiligo from the internet and social media. The number of participants may limit the generalizability of the findings. Survey questionnaires are also subject to response bias. The findings from this study highlight demographic variations in sunscreen usage which may help guide the development of targeted interventions to improve sun protective behaviors among diverse populations with vitiligo. In addition, this study suggests certain sun protective practices and skin cancer risk perceptions may vary based on extent of depigmentation. Lastly, this study also demonstrates the internet and social media as a popular source for obtaining information, emphasizing the need for dermatologists to leverage various online communication channels to help disseminate accurate information.

dermatology
A 4-year follow-up study of 20 cases of stable localized childhood vitiligo treated by autologous, noncultured melanocyte–keratinocyte cell transplantation

Ettappurath N Abdul Latheef,S. Rahima,K. Muhammed,Najeeba Riyaz

DOI: https://doi.org/10.4103/pigmentinternational.pigmentinternational_54_21

2023-03-24

Pigment International

Abstract:Background: Vitiligo is a common skin disease affecting 1% to 2% of general population. Even though different modalities of treatment available, it remains as a difficult disease to treat. Many cases remain stable after a period of medical therapy without any further response. For treating pediatric vitiligo, currently available and result providing therapies are limited. Surgical techniques are the only hope in such patients. Only limited studies are available regarding surgical interventions in childhood vitiligo. Aim: To evaluate the response of autologous, noncultured melanocyte–keratinocyte cell transplantation in childhood stable vitiligo. Methods: A retrospective analysis was conducted in 20 cases of stable localized childhood vitiligo (10 segmental and 10 focal) treated by autologous, noncultured melanocyte–keratinocyte cell transplantation. Serial photographs were taken from the first visit onwards. The patients were followed for a period of 4 years. The results were analyzed on a visual analog scale. Results: Out of total 20 cases, 11 had excellent (90–100%) response, 4 had good (60–89%), 2 had fair (25–59%), and 3 had poor response (0–24%). Age and sex of the patients and size and duration of lesions did not show significant influence on results of transplantation. Conclusion: This is a simple, safe, and effective surgical therapy for replenishing the missing melanocytes even in resistant cases of vitiligo. Only limited studies are there in childhood vitiligo. In spite of its invasive nature, it can be used to treat localized stable vitiligo in children.
A Review of the Vitiligo Literature to Standardize Expression of Disease Severity

Yael Renert-Yuval,Seemal Desai,Victor Huang,Samantha Walsh,David Rosmarin,Nanette Silverberg

DOI: https://doi.org/10.36849/JDD.2024.8049

2024-10-01

Abstract:Background: The literature on vitiligo is heterogeneous with limited standardization in vitiligo disease severity reporting. Objectives: The IDEOM Vitiligo Workgroup initiated a project to develop an improved understanding of clinical reporting of vitiligo severity. Methods: A medical librarian-developed literature review identified 50 clinical trials treating vitiligo topically using topical corticosteroids or topical tacrolimus that included adult and pediatric patients, with 10 or more patients, with grading by SORT criteria. Results: Grading systems used included body surface area scoring (BSA) clinically or via photography and mapping. Most studies create a grading system of repigmentation including G0- no change, G1- 1-25%, G2- 26-50%, G3- 51-75%, G4- 75-99%, and G5- 100%. Variations include reporting success as thresholds >25% (G2-G5), >50% (G3-G5), and >75% (G4-G5) repigmentation. Vitiligo Area Scoring Index (VASI), Dermatology Life Quality Index (DLQI), patient satisfaction, and the vitiligo noticeability scale are all standardized scoring systems that have been used in clinical studies. Other metrics reported include onset and maintenance of response, treatment burden, side effects, and cost-effectiveness. Conclusions: BSA total and quartiles of improvement are the most commonly reported metrics in studies with high-level evidence. The addition of categories of no improvement, complete clearance, spontaneous improvement, and worsening appears to enhance information collection. Collection of data using photographs or computer-assisted BSA monitoring enhances data reproducibility. Thresholds of success should include 25%, 50%, 75%, and adding 90% and 100% repigmentation. VASI represents a validated collection method, which can be modified for 50%, 75%, and 90% improvement. Newer metrics including treatment burden and cost effectiveness are emerging metrics under evaluation. J Drugs Dermatol. 2024;23(10):842-846. doi:10.36849/JDD.8049.
Clinical and Immunological Features of Childhood Vitiligo

LIN Xiao,FU Wen-wen

DOI: https://doi.org/10.3760/cma.j.issn.1673-4173.2008.04.003

2008-01-01

International Journal of Dermatology and Venereology

Abstract:Objective To discuss the relationship between immunity and childhood vitiligo. Methods A questionnaire was designed to investigate the clinical characteristic of patients younger than 14 years with vi-tiligo and their relatives. The serum levels of immunoglobulin, complement and T-lymphocyte subsets were de-tected in 270 cases of pediatric vitiligo. Results A total of 620 patients were investigated. Of them, 302(48.71%) were boys and 318 (51.29% ) were girls, with a mean age of 8.81 years and mean onset age at 7.57years. The mean disease duration was 8.14 months. The involvement of head and neck was observed in 453(73.06%) children. Segmental vitiligo was diagnosed in 160 (25.81%) children. Spring and summer are predilected seasons of pediatric vitiligo. Halo nevi were found in 73 (11.77%) children,and most in those with scattered vitiligo. Family history was observed in 84 (13.55%) children. A significant decrease of serum C3 and C4 was observed in patients with segmental vitiligo in active phase compared with those in stable phase (P < 0.05). Similarly, the count of CD4+ and CD3+ lymphocytes in peripheral blood as well as the CD4+/CD8+ ratio were decreased in patients with vitiligo vulgaris in active phase compared with those in stable phase (P<0.01).Conclusion There is an abnormality in some immune parameters in children with vitiligo, which may be relat-ed to the immunologic derangement.
Current and emerging treatments for vitiligo

Michelle Rodrigues,Khaled Ezzedine,Iltefat Hamzavi,Amit G. Pandya,John E. Harris,Vitiligo Working Group

DOI: https://doi.org/10.1016/j.jaad.2016.11.010

IF: 15.487

2017-07-01

Journal of the American Academy of Dermatology

Abstract:Clinicians should be aware that vitiligo is not merely a cosmetic disease and that there are safe and effective treatments available for vitiligo. It is important to recognize common and uncommon presentations and those with active disease, as well as their implications for clinical management; these were discussed in the first article in this continuing medical education series. Existing treatments include topical and systemic immunosuppressants, phototherapy, and surgical techniques, which together may serve to halt disease progression, stabilize depigmented lesions, and encourage repigmentation. We discuss how to optimize the currently available treatments and highlight emerging treatments that may improve treatment efficacy in the future.

dermatology
José M. Seco, Emilio Quiñoá, and Ricardo Riguera: The assignment of the absolute configuration by NMR using chiral derivatizing agents: a practical guide

T. Wenzel

DOI: https://doi.org/10.1007/s00216-015-9062-y

2015-10-05

Analytical and Bioanalytical Chemistry

Abstract:

Aseptic necrosis of the knee: bone scintigraphy.

Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients

Guideline for the diagnosis and management of vitiligo

Update on childhood vitiligo

Childhood facial vitiligo: how intractable is it?

Practices in Pediatric Cosmetic Dermatologic Procedures: A National Survey

Pediatric Dermatology for People of Color

Therapeutic interventions to lessen the psychosocial effect of vitiligo in children: A review

Antigen‐antibody combination assays for blood donor screening: weighing the advantages and costs

Vitiligo outpatient management in the United States: findings from the 2012–2019 National Ambulatory Medical care Survey (NAMCS)

Prevalence of psychiatric comorbidities and treatment initiation in African American pediatric patients with vitiligo: A retrospective, single-center, case-control study

Real-World Experience of Vitiligo Patients: A Retrospective Chart Review

Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force—Part 2: Specific treatment recommendations

Dermatology for the pediatrician: Advances in diagnosis and treatment of common and not-so-common skin conditions

Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy

Perception of skin cancer risk and sun protective practices in individuals with vitiligo: a prospective international cross-sectional survey

A 4-year follow-up study of 20 cases of stable localized childhood vitiligo treated by autologous, noncultured melanocyte–keratinocyte cell transplantation

A Review of the Vitiligo Literature to Standardize Expression of Disease Severity

Clinical and Immunological Features of Childhood Vitiligo

Current and emerging treatments for vitiligo

José M. Seco, Emilio Quiñoá, and Ricardo Riguera: The assignment of the absolute configuration by NMR using chiral derivatizing agents: a practical guide